Adverts

Open Access Articles- Top Results for CP-615,003

CP-615,003

</th></tr>
CP-615,003
File:CP-615003 structure.png
Systematic (IUPAC) name
N-(3-fluoro-4-(2-(propylamino)ethoxy)phenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide
Clinical data
Identifiers
329016-45-7 7pxY
PubChem CID 9820874
Chemical data
Formula C20H24FN3O3
373.421 g/mol
 14pxY (what is this?)  (verify)

CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic, however poor blood–brain barrier penetration make it primarily useful as a research ligand.[1][2]

References

  1. ^ Shaffer CL, Gunduz M, O'Connell TN, Obach RS, Yee S (November 2005). "Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites". Drug Metabolism and Disposition: the Biological Fate of Chemicals 33 (11): 1688–99. PMID 16081672. doi:10.1124/dmd.105.004630. 
  2. ^ Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA (August 2007). "Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures". Drug Metabolism and Disposition: the Biological Fate of Chemicals 35 (8): 1341–9. PMID 17470526. doi:10.1124/dmd.106.013953.